FDA.reportPublic FDA data

Lumryz 28-Day Starter Pack

RxCUI
2698136
RxNorm name
Lumryz 28-Day Starter Pack
Display name
Lumryz 28-Day Starter Pack
Full name
Lumryz 28-Day Starter Pack
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LumryzSODIUM OXYBATEAvadel CNS Pharmaceuticals, LLC10e5e40c-52f3-4c73-8a34-2c29c690a9342025-12-04Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2698136

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
10e5e40c-52f3-4c73-8a34-2c29c690a934Lumryz 28-Day Starter PackPSN10These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204
10e5e40c-52f3-4c73-8a34-2c29c690a934Lumryz 28-Day Starter PackSY10These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204
10e5e40c-52f3-4c73-8a34-2c29c690a934{7 (sodium oxybate 4500 MG Granules for Oral Suspension [Lumryz]) / 14 (sodium oxybate 6000 MG Granules for Oral Suspension [Lumryz]) / 7 (sodium oxybate 7500 MG Granules for Oral Suspension [Lumryz]) } Pack [Lumryz 28-Day Starter Pack]BPCK10These highlights do not include all the information needed to use LUMRYZ™ safely and effectively. See full prescribing information for LUMRYZ. LUMRYZ (sodium oxybate) for extended-release oral suspension, CIII Initial U.S. Approval: 200220251204